KIF2C as a potential therapeutic target: insights from lung adenocarcinoma subtype classification and functional experiments†

IF 3 4区生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY

Molecular omics Pub Date : 2024-06-18 DOI:10.1039/D4MO00044G

Zhi Xu, Rui Miao, Tao Han, Yafeng Liu, Jiawei Zhou, Jianqiang Guo, Yingru Xing, Ying Bai, Jing Wu and Dong Hu

{"title":"KIF2C as a potential therapeutic target: insights from lung adenocarcinoma subtype classification and functional experiments†","authors":"Zhi Xu, Rui Miao, Tao Han, Yafeng Liu, Jiawei Zhou, Jianqiang Guo, Yingru Xing, Ying Bai, Jing Wu and Dong Hu","doi":"10.1039/D4MO00044G","DOIUrl":null,"url":null,"abstract":"\r\n Objective: this study evaluates the prognostic relevance of gene subtypes and the role of kinesin family member 2C (KIF2C) in lung cancer progression. Methods: high-expression genes linked to overall survival (OS) and progression-free interval (PFI) were selected from the TCGA-LUAD dataset. Consensus clustering analysis categorized lung adenocarcinoma (LUAD) patients into two subtypes, C1 and C2, which were compared using clinical, drug sensitivity, and immunotherapy analyses. A random forest algorithm pinpointed KIF2C as a prognostic hub gene, and its functional impact was assessed through various assays and in vivo experiments. Results: The study identified 163 key genes and distinguished two LUAD subtypes with differing OS, PFI, pathological stages, drug sensitivity, and immunotherapy response. KIF2C, highly expressed in the C2 subtype, was associated with poor prognosis, promoting cancer cell proliferation, migration, invasion, and epithelial–mesenchymal transition (EMT), with knockdown reducing tumor growth in mice. Conclusion: The research delineates distinct LUAD subtypes with significant clinical implications and highlights KIF2C as a potential therapeutic target for personalized treatment in LUAD.","PeriodicalId":19065,"journal":{"name":"Molecular omics","volume":" 6","pages":" 417-429"},"PeriodicalIF":3.0000,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular omics","FirstCategoryId":"99","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2024/mo/d4mo00044g","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: this study evaluates the prognostic relevance of gene subtypes and the role of kinesin family member 2C (KIF2C) in lung cancer progression. Methods: high-expression genes linked to overall survival (OS) and progression-free interval (PFI) were selected from the TCGA-LUAD dataset. Consensus clustering analysis categorized lung adenocarcinoma (LUAD) patients into two subtypes, C1 and C2, which were compared using clinical, drug sensitivity, and immunotherapy analyses. A random forest algorithm pinpointed KIF2C as a prognostic hub gene, and its functional impact was assessed through various assays and in vivo experiments. Results: The study identified 163 key genes and distinguished two LUAD subtypes with differing OS, PFI, pathological stages, drug sensitivity, and immunotherapy response. KIF2C, highly expressed in the C2 subtype, was associated with poor prognosis, promoting cancer cell proliferation, migration, invasion, and epithelial–mesenchymal transition (EMT), with knockdown reducing tumor growth in mice. Conclusion: The research delineates distinct LUAD subtypes with significant clinical implications and highlights KIF2C as a potential therapeutic target for personalized treatment in LUAD.

Abstract Image

查看原文本刊更多论文

作为潜在治疗靶点的 KIF2C：肺腺癌亚型分类和功能实验的启示。

目的：本研究评估了基因亚型的预后相关性以及驱动蛋白家族成员 2C（KIF2C）在肺癌进展中的作用。方法：从 TCGA-LUAD 数据集中筛选出与总生存期（OS）和无进展间期（PFI）相关的高表达基因。共识聚类分析将肺腺癌（LUAD）患者分为C1和C2两种亚型，并通过临床、药物敏感性和免疫疗法分析对这两种亚型进行了比较。随机森林算法将KIF2C定位为预后枢纽基因，并通过各种测定和体内实验评估其功能影响。研究结果研究发现了163个关键基因，并区分出了两种LUAD亚型，它们的OS、PFI、病理分期、药物敏感性和免疫治疗反应各不相同。在C2亚型中高表达的KIF2C与预后不良有关，它能促进癌细胞增殖、迁移、侵袭和上皮-间质转化（EMT），敲除KIF2C能减少小鼠的肿瘤生长。结论该研究划分了具有重要临床意义的不同LUAD亚型，并强调KIF2C是LUAD个性化治疗的潜在治疗靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular omics Biochemistry, Genetics and Molecular Biology-Biochemistry

CiteScore

5.40

自引率

3.40%

发文量

期刊介绍： Molecular Omics publishes high-quality research from across the -omics sciences. Topics include, but are not limited to: -omics studies to gain mechanistic insight into biological processes – for example, determining the mode of action of a drug or the basis of a particular phenotype, such as drought tolerance -omics studies for clinical applications with validation, such as finding biomarkers for diagnostics or potential new drug targets -omics studies looking at the sub-cellular make-up of cells – for example, the subcellular localisation of certain proteins or post-translational modifications or new imaging techniques -studies presenting new methods and tools to support omics studies, including new spectroscopic/chromatographic techniques, chip-based/array technologies and new classification/data analysis techniques. New methods should be proven and demonstrate an advance in the field. Molecular Omics only accepts articles of high importance and interest that provide significant new insight into important chemical or biological problems. This could be fundamental research that significantly increases understanding or research that demonstrates clear functional benefits. Papers reporting new results that could be routinely predicted, do not show a significant improvement over known research, or are of interest only to the specialist in the area are not suitable for publication in Molecular Omics.